Wendling D, Racadot E, Wijdenes J
Service de Rhumatologie, Hôpital Jean Minjoz, Centre Hospitalier Universitaire, Besancon, France.
J Rheumatol. 1993 Feb;20(2):259-62.
Interleukin 6 (IL-6) appears to be a potential mediator of inflammation that may contribute to the pathogenesis of joint inflammation in RA. Anti-IL-6 monoclonal antibodies (Mab) may represent a new tool in RA treatment. Five patients with RA, after previous anti-CD4 therapy (B-F5) without antimouse immunization were included in our open pilot study. The anti-IL-6 Mab (B-E8, IgG1) was given intravenously (10 mg/day) for 10 consecutive days in hospital. No side effects were noted. Clinical and biological (C-reactive protein) improvement appeared during the treatment period. However improvement was transitory (mean: 2 months). Unexpectedly serum IL-6 levels increased in 4 patients with this treatment that seemed to have antiinflammatory effects. Further studies are required to evaluate the real benefit and the mode of action of this Mab.
白细胞介素6（IL-6）似乎是一种潜在的炎症介质，可能在类风湿性关节炎（RA）的关节炎症发病机制中起作用。抗IL-6单克隆抗体（Mab）可能成为RA治疗的一种新工具。我们的开放性初步研究纳入了5例先前接受过抗CD4治疗（B-F5）且未进行抗小鼠免疫的RA患者。抗IL-6 Mab（B-E8，IgG1）在医院连续10天静脉注射（10毫克/天）。未观察到副作用。治疗期间临床和生物学指标（C反应蛋白）有所改善。然而，改善是短暂的（平均2个月）。出乎意料的是，4例接受该治疗的患者血清IL-6水平升高，而该治疗似乎具有抗炎作用。需要进一步研究来评估这种Mab的实际益处和作用方式。
